Bicycle Therapeutics plc Financing Cash Flow
Bicycle Therapeutics plc (BCYC) reported Financing Cash Flow of -$104.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-07-30
- Bicycle Therapeutics plc net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was -$50.00K.
- Bicycle Therapeutics plc net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was -$54.00K.
- Bicycle Therapeutics plc net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was -$15.00K, a 107.39% decline year-over-year.
- Bicycle Therapeutics plc net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was -$30.00K.
- Bicycle Therapeutics plc net cash provided by (used in) financing activities for fiscal 2025 was -$131.00K, a 100.03% decline from fiscal 2024.
- Bicycle Therapeutics plc net cash provided by (used in) financing activities for fiscal 2024 was $519.75M, a 107.88% increase from fiscal 2023.
- Bicycle Therapeutics plc net cash provided by (used in) financing activities for fiscal 2023 was $250.03M, a 3636.21% increase from fiscal 2022.
- Bicycle Therapeutics plc net cash provided by (used in) financing activities for fiscal 2022 was $6.69M, a 97.91% decline from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$50.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | -$104.00K 10-Q · filed 2026-07-30 | -$119.00K derived: sum of 3 quarters · filed 2026-07-30 | -$149.00K derived: sum of 4 quarters · filed 2026-07-30 |
| 2026-03-31 | -$54.00K 10-Q · filed 2026-04-30 | -$69.00K derived: sum of 2 quarters · filed 2026-04-30 | -$99.00K derived: sum of 3 quarters · filed 2026-04-30 | -$144.00K derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-12-31 | -$15.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | -$45.00K derived: sum of 2 quarters · filed 2026-03-17 | -$90.00K derived: sum of 3 quarters · filed 2026-07-30 | -$131.00K 10-K · filed 2026-03-17 |
| 2025-09-30 | -$30.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | -$75.00K derived: sum of 2 quarters · filed 2026-07-30 | -$116.00K 10-Q · filed 2025-10-30 | $87.00K derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-06-30 | -$45.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | -$86.00K 10-Q · filed 2026-07-30 | $117.00K derived: sum of 3 quarters · filed 2026-07-30 | -$31.81M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-03-31 | -$41.00K 10-Q · filed 2026-04-30 | $162.00K derived: sum of 2 quarters · filed 2026-04-30 | -$31.77M derived: sum of 3 quarters · filed 2026-04-30 | $517.84M derived: sum of 4 quarters · filed 2026-04-30 |
| 2024-12-31 | $203.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | -$31.73M derived: sum of 2 quarters · filed 2026-03-17 | $517.88M derived: sum of 3 quarters · filed 2026-03-17 | $519.75M 10-K · filed 2026-03-17 |
| 2024-09-30 | -$31.93M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | $517.68M derived: sum of 2 quarters · filed 2025-10-30 | $519.55M 10-Q · filed 2025-10-30 | $519.93M derived: sum of 4 quarters · filed 2026-03-17 |
| 2024-06-30 | $549.61M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-08 | $551.48M 10-Q · filed 2025-08-08 | $551.86M derived: sum of 3 quarters · filed 2026-03-17 | $786.49M derived: sum of 4 quarters · filed 2026-03-17 |
| 2024-03-31 | $1.87M 10-Q · filed 2025-05-01 | $2.26M derived: sum of 2 quarters · filed 2026-03-17 | $236.89M derived: sum of 3 quarters · filed 2026-03-17 | $249.18M derived: sum of 4 quarters · filed 2026-03-17 |
| 2023-12-31 | $386.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $235.02M derived: sum of 2 quarters · filed 2026-03-17 | $247.31M derived: sum of 3 quarters · filed 2026-03-17 | $250.03M 10-K · filed 2026-03-17 |
| 2023-09-30 | $234.63M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | $246.92M derived: sum of 2 quarters · filed 2024-10-31 | $249.64M 10-Q · filed 2024-10-31 | $255.53M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-06-30 | $12.29M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $15.01M 10-Q · filed 2024-08-06 | $20.90M derived: sum of 3 quarters · filed 2025-02-25 | $21.06M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-03-31 | $2.72M 10-Q · filed 2024-05-02 | $8.61M derived: sum of 2 quarters · filed 2025-02-25 | $8.77M derived: sum of 3 quarters · filed 2025-02-25 | $8.96M derived: sum of 4 quarters · filed 2025-02-25 |
| 2022-12-31 | $5.89M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $6.05M derived: sum of 2 quarters · filed 2025-02-25 | $6.24M derived: sum of 3 quarters · filed 2025-02-25 | $6.69M 10-K · filed 2025-02-25 |
| 2022-09-30 | $159.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $354.00K derived: sum of 2 quarters · filed 2023-11-02 | $804.00K 10-Q · filed 2023-11-02 | $191.47M derived: sum of 4 quarters · filed 2024-02-20 |
| 2022-06-30 | $195.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $645.00K 10-Q · filed 2023-08-03 | $191.31M derived: sum of 3 quarters · filed 2024-02-20 | $231.76M derived: sum of 4 quarters · filed 2024-02-20 |
| 2022-03-31 | $450.00K 10-Q · filed 2023-05-04 | $191.11M derived: sum of 2 quarters · filed 2024-02-20 | $231.56M derived: sum of 3 quarters · filed 2024-02-20 | $247.12M derived: sum of 4 quarters · filed 2024-02-20 |
| 2021-12-31 | $190.66M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-20 | $231.11M derived: sum of 2 quarters · filed 2024-02-20 | $246.67M derived: sum of 3 quarters · filed 2024-02-20 | $320.73M 10-K · filed 2024-02-20 |
| 2021-09-30 | $40.45M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $56.00M derived: sum of 2 quarters · filed 2022-11-03 | $130.06M 10-Q · filed 2022-11-03 | $131.81M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | $15.55M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $89.61M 10-Q · filed 2022-08-04 | $91.36M derived: sum of 3 quarters · filed 2023-02-28 | $152.44M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | $74.06M 10-Q · filed 2022-05-05 | $75.80M derived: sum of 2 quarters · filed 2023-02-28 | $136.89M derived: sum of 3 quarters · filed 2023-02-28 | $136.90M derived: sum of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | $1.74M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $62.83M derived: sum of 2 quarters · filed 2023-02-28 | $62.84M derived: sum of 3 quarters · filed 2023-02-28 | $62.84M 10-K · filed 2023-02-28 |
| 2020-09-30 | $61.09M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $61.10M derived: sum of 2 quarters · filed 2021-11-04 | $61.10M 10-Q · filed 2021-11-04 | $61.22M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-06-30 | $10.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $12.00K 10-Q · filed 2021-08-05 | $134.00K derived: sum of 3 quarters · filed 2022-03-01 | -$677.00K derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-03-31 | $2.00K 10-Q · filed 2021-05-06 | $124.00K derived: sum of 2 quarters · filed 2022-03-01 | -$687.00K derived: sum of 3 quarters · filed 2022-03-01 | $58.41M derived: sum of 4 quarters · filed 2022-03-01 |
| 2019-12-31 | $122.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | -$689.00K derived: sum of 2 quarters · filed 2022-03-01 | $58.41M derived: sum of 3 quarters · filed 2022-03-01 | $58.44M 10-K · filed 2022-03-01 |
| 2019-09-30 | -$811.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $58.28M derived: sum of 2 quarters · filed 2020-11-05 | $58.32M 10-Q · filed 2020-11-05 | $83.75M derived: sum of 4 quarters · filed 2021-03-11 |
| 2019-06-30 | $59.09M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-05 | $59.13M 10-Q · filed 2020-08-05 | $84.56M derived: sum of 3 quarters · filed 2021-03-11 | |
| 2019-03-31 | $34.00K 10-Q · filed 2020-05-07 | $25.46M derived: sum of 2 quarters · filed 2021-03-11 | ||
| 2018-12-31 | $25.43M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-11 | $25.43M 10-K · filed 2021-03-11 | ||
| 2018-09-30 | $1.00K 10-Q · filed 2019-11-07 | |||
| 2017-12-31 | $57.88M 10-K · filed 2020-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| ProMIS Neurosciences Inc. (PMN) | $0.102B |